25 December 2012 | Opinion | By BioSpectrum Bureau
Dr Steven Fang, partner, Clearbridge Accelerator, Singapore
I foresee a number of interesting upcoming trends within the biomedical sector, including a shift from pharmaceutical-based compounds to biopharmaceuticals, as well as the rapid development of biologics and biosimilars. I also expect to see the introduction of novel drug screening and developmental pathways in 2013. As regenerative medicine is something close to my heart, I hope to see more developments in this area next year too. From the business point of view, I believe there will be an increase in the number of M&A deal flows, as a result of the current weak funding market.
As a new partner in Clearbridge Accelerator, I will be working with the team to create the next generation of successful global medical and life sciences companies. In particular, this will involve providing mentorship and guidance to help incubatee companies to commercialize their ground-breaking technologies into globally-marketable products. I will also be working with our investee companies to explore relevant growth and exit opportunities.